Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

This publication has 28 references indexed in Scilit:

• A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
  British Journal of Cancer, 2004
• Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
  Gynecologic Oncology, 2004
• Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
  Gynecologic Oncology, 2004
• Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective
  International Journal of Gynecologic Cancer, 2003
• Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
  Journal of Clinical Oncology, 2003
• Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5
  Gynecologic Oncology, 2003
• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
  Cancer, 2000
• 543: Phase 1 study to investigate alternate sequencing of the combination of gemcitablne and paclitaxel in ovarian carcinoma
  European Journal Of Cancer, 1997
• Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients
  JNCI Journal of the National Cancer Institute, 1994